SWAP-7NCT06691191
Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors
At risk: Primary completion moved 4 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 3 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 14 words
- Primary completion pushed from Aug 31, 2026 to Dec 31, 2026
- Study completion pushed from Dec 31, 2026 to Apr 30, 2027
- Study description revised
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Jan 1, 2025 to Jan 8, 2025
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Platelet reactivity measured by VerifyNow
Timeframe: 21±7 days
Arms and interventions
Ticagrelor monotherapyActive comparator
Ticagrelor 90 mg bid monotherapy for 21±7 days
Prasugrel monotherapyExperimental
Prasugrel 10 mg qd for 21±7 days
Drugs: Ticagrelor 90 mg, Prasugrel 10 mg
Sites
1 site in 1 country
- University of Florida JacksonvilleJacksonville, Florida, United States